RESMED, INC.

(RMD)
  Report
Delayed Nyse  -  05/18 04:00:01 pm EDT
191.41 USD   -3.25%
04:06pEVEN 2 HOURS OF PAP THERAPY PER NIGHT BENEFITS SLEEP APNEA SUFFERERS : ResMed Study
GL
04:05pEVEN 2 HOURS OF PAP THERAPY PER NIGHT BENEFITS SLEEP APNEA SUFFERERS : ResMed Study
AQ
05/17INSIDER SELL : Resmed
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ResMed Receives Price Target Boost to $234 From $227 From RBC on 'Positive Implications" From Philips Update; Underperform Kept

01/13/2022 | 10:27am EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ON SEMICONDUCTOR CORPORATION -4.56% 55.83 Delayed Quote.-17.80%
PHILIPS NV -0.77% 23.725 Real-time Quote.-27.59%
RESMED, INC. -3.25% 191.41 Delayed Quote.-26.52%
All news about RESMED, INC.
04:06pEVEN 2 HOURS OF PAP THERAPY PER NIGH : ResMed Study
GL
04:05pEVEN 2 HOURS OF PAP THERAPY PER NIGH : ResMed Study
AQ
05/17INSIDER SELL : Resmed
MT
05/11RESMED INC : Change in Directors or Principal Officers, Financial Statements and Exhibits ..
AQ
05/11RESMED, INC. : Ex-dividend day for
FA
05/05Insulet Reports Q1 Profit , Names New CEO
MT
05/05ResMed Announces Leadership Change
GL
05/05ResMed Inc. Announces Management Changes
CI
05/04INSIDER SELL : Resmed
MT
05/02TRANSCRIPT : ResMed Inc. Presents at 24th Annual Macquarie Australia Conference, May-03-20..
CI
More news
Analyst Recommendations on RESMED, INC.
More recommendations
Financials (USD)
Sales 2022 3 581 M - -
Net income 2022 780 M - -
Net Debt 2022 375 M - -
P/E ratio 2022 36,1x
Yield 2022 0,88%
Capitalization 28 000 M 28 000 M -
EV / Sales 2022 7,92x
EV / Sales 2023 6,93x
Nbr of Employees 7 970
Free-Float 77,1%
Chart RESMED, INC.
Duration : Period :
ResMed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESMED, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 191,41 $
Average target price 243,13 $
Spread / Average Target 27,0%
EPS Revisions
Managers and Directors
Michael J. Farrell Director-Business Development
Robert Andrew Douglas Vice President-Corporate Marketing
Brett A. Sandercock Chief Financial Officer
Peter C. Farrell Non-Executive Chairman
Carlos M. Nunez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
RESMED, INC.-26.52%28 939
THERMO FISHER SCIENTIFIC-19.16%217 105
DANAHER CORPORATION-24.33%178 236
INTUITIVE SURGICAL, INC.-37.33%80 830
SIEMENS HEALTHINEERS AG-14.68%66 343
EDWARDS LIFESCIENCES CORPORATION-24.82%60 552